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Abstract
The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic
outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual
effect of antibiotic resistance on clinical outcomes is a necessary ﬁrst step. In this article, we review and discuss the contributions and
limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of
resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic
resistance.
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Introduction
The introduction of antibiotics, along with public health
improvements in sanitation, hygiene, and safe drinking water,
was associated with an accelerated decline in infectious
disease-related mortality in the USA during the 20th century
[1,2]. Clinical studies have shown that the mortality reduction
with antibiotics ranges from 10% for skin infections to 75% for
bacterial endocarditis [3]. Antibiotics have been pivotal in
treating and preventing common infections, but their overuse
and misuse have contributed to an alarming increase in
antibiotic resistance worldwide. With a declining choice of
antibiotics, we have entered a ‘post-antibiotic’ era [4,5].
Several studies have shown that antibiotic-resistant infec-
tions are associated with increased morbidity and mortality as
compared with antibiotic-susceptible infections; however,
quantifying the disease burden with any degree of accuracy
has proven difﬁcult, and existing studies have major method-
ological limitations and biases [6–9]. Accurately quantifying the
effect of antibiotic resistance on clinical outcomes is essential
for estimating the associated economic burden. In this article,
we review the existing estimates of disease and economic
burdens attributable to antibiotic-resistant bacterial infections
(excluding tuberculosis). We summarize the limitations of
these studies, and discuss ways to more accurately quantify the
disease and economic burdens attributable to antibiotic
resistance.
Limitations and Reasons for Variability in
Studies Estimating the Disease Burden of
Antibiotic Resistance
Estimating the morbidity and mortality burden attributable to
antibiotic-resistant infections is necessary before evaluating the
economic burden of antibiotic resistance, as the economic
burden is directly related to the disease burden. Existing
cohort studies focusing on the disease burden are subject to
methodological limitations, however, and these limitations
make it difﬁcult to accurately assess the true burden of disease.
Previous reviews [6–9] have discussed these drawbacks in
detail: they include failure to adjust for important factors such
as length of hospital stay prior to onset of infection, severity of
underlying illness, comorbidities, and effective antibiotic
therapy (Table 1).
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In addition, current estimates of disease burden vary widely
because of heterogeneity in study populations, control groups,
causative pathogens with different virulence and pathogenic
potential, locations of infection site, deﬁnitions of resistance,
and variation in follow-up time (Table 2). Recent studies [10–
12] have addressed these methodological limitations by using a
matched-cohort design to match patients infected with
resistant strains to control patients infected with susceptible
strains who have similar hospital exposure. Although these
matched study designs increase the comparability of the risk
proﬁles between infected and control patients, they do not
consider the time-dependent nature of antibiotic-resistant
infections.
Time-dependent bias occurs when the exposure (infection)
varies over time but is analysed as though the exposure was a
ﬁxed event. Thus, patients are labelled as either ‘infected’ or
‘uninfected’ even before outcomes of interest occur [13].
Previous studies have demonstrated that disregarding the
time-dependent nature of hospital-acquired infections results
in overestimation of the morbidity (measured by excess length
of stay (LOS)) attributable to these infections. For instance,
Beyersmann et al. [14] studied the effects of nosocomial
pneumonia LOS in intensive-care units (ICUs) by considering
nosocomial pneumonia as a time-dependent vs. time-ﬁxed
variable. In both cases, the nosocomial pneumonia prolonged
LOS. However, in the time-ﬁxed analysis, the effect was
overestimated: the hazard ratios considering pneumonia as
time-dependent vs. time-ﬁxed for ICU LOS were 0.75 vs. 0.36.
Similarly, Barnett et al. [15] looked at the effects of nosocomial
infection on excess LOS in a large prospective cohort study of
TABLE 1. Methodological limitations in studies assessing the disease burden attributable to antibiotic-resistant infections
Weakness Description Example
Failure to adjust for hospital stay prior to
onset of infection
Prolonged hospitalization increases the risk of
antibiotic-resistant infections and death. Lack of
adjustment for LOS prior to onset of infection could
result in an overestimation of the effect of resistance
on clinical outcomes
Schlugen et al. [83] showed that excess LOS decreases when
patients with hospital-acquired pneumonia are matched by
LOS prior to onset of infection
Failure to adjust for severity of underlying
illness and comorbidities
Patients with antibiotic-resistant infections often have
underlying illnesses and comorbidities, which lead to
adverse outcomes independently of resistance. Lack
of adjustment for these variables could result in an
overestimation of the effect of resistance on clinical
outcomes
Thom et al. [84] showed that adjusting for severity of illness
decreased the impact of appropriate therapy on in-hospital
mortality
Failure to adjust for effective antibiotic
therapy
The likelihood of receiving appropriate empirical
antibiotic therapy may be low for patients with
antibiotic-resistant infections. Inappropriate
antibiotic therapy alone can have adverse clinical
outcomes. Not adjusting for appropriate antibiotic
therapy could result in an overestimation of the
effect of antibiotic resistance on adverse clinical
outcomes
In a meta-analysis, Rottier et al. [85] assessed the impact of
inadequate antibiotic therapy on mortality associated with
ESBL-producing Enterobacteriaceae. Studies adjusting for
inadequate empirical therapy had lower ORs of mortality than
those that did not (OR 1.37, 95% CI 1.04–1.82 vs. OR 2.77,
95% CI 2.13–3.60)
Failure to consider exposure as
time-dependent
Time-dependent bias occurs when the time-varying
nature of antibiotic-resistant infections is ignored.
This can result in an overestimation of the effect of
resistance on clinical outcomes
Beyersmann et al. [86] studied the effect of nosocomial
pneumonia on LOS in ICU patients by considering nosocomial
pneumonia as a time-dependent vs. a time-ﬁxed variable. In
both cases, nosocomial pneumonia prolonged LOS; however,
in time-ﬁxed analysis, the effect was overestimated (HR 0.75
vs. HR 0.36)
ESBL, extended-spectrum b-lactamase; HR, hazard ratio; ICU, intensive-care unit; LOS, length of stay; OR, odds ratio.
TABLE 2. Reasons for variability in outcomes of antibiotic-resistant infections
Variable Description
Heterogeneity in study population Estimates of clinical outcomes resulting from antibiotic-resistant infections vary by study population. For example, in a meta-analysis [20]
comparing mortality associated with MRSA vs. MSSA bacteraemia, the pooled OR was signiﬁcantly higher for MRSA. However, subgroup
analysis showed that the OR varied according to the characteristics of study subjects (e.g. percentage with nosocomial infections,
endocarditis, and line infections)
Inadequate sample size Studies with small sample sizes can have wide CIs for estimating clinical outcomes
Type of control group Estimates of the clinical outcomes of antibiotic-resistant infections differ greatly by control group. If the control group comprises
uninfected patients rather than those infected with susceptible strains, adverse outcomes resulting from antibiotic resistance will be
more frequent
Causative pathogens Different pathogens vary in their virulence and pathogenic potential, which can directly affect clinical outcomes
Location of infection site Outcomes of antibiotic resistance depend on the primary source of infection. For example, patients with bacteraemia resulting from
endocarditis or intra-abdominal infection have more adverse outcomes than patients with line infections
Deﬁnitions of resistance Deﬁnitions of resistance for certain pathogens (such as MRSA, VRE, and ESBL-positive Enterobacteriaceae) are straightforward. However,
deﬁnitions of resistance for Pseudomonas or Acinetobacter species vary. Outcomes may differ with extent of resistance
(multidrug-resistant vs. extremely drug-resistant vs. pan-drug-resistant) because treatment options differ
Follow-up time Outcomes of antibiotic-resistant infections differ in studies with varying follow-up times: greater follow-up time makes it more likely that
long-term effects of resistant infections can be assessed. For example, studies considering mortality three months after onset of
infection may have higher mortality rates than studies considering in-hospital mortality only
CIs, conﬁdence intervals; ESBL, extended-spectrum b-lactamase; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; OR, odds
ratio; VRE, vancomycin-resistant Enterococcus.
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patients admitted to a hospital in Argentina by considering
nosocomial infection as a time-dependent vs. time-ﬁxed
variable. The results demonstrated that the excess LOS
attributable to nosocomial infection decreased from
11.23 days to 1.35 days after adjustment for timing of
infection.
Methods for Controlling for Time-
dependent Bias
To control for time-dependent bias, recent studies [16–19]
have used multistate models—continuous-time models that
allow individuals to randomly move among a ﬁxed number of
states—such that individuals are not assigned a ﬁxed event
time [13]. Individuals move from one state to another when
events occur, and thus the composition of infected and
uninfected patients changes over time. Studies that control for
time-dependent bias by using multistate models report more
conservative estimates of morbidity and mortality than studies
that do not control for time of infection [16–18]. For instance,
Macedo-Vinas et al. [18] estimated excess LOS for patients
with methicillin-resistant Staphylococcus aureus (MRSA) infec-
tions at a single site by using both multistate and matched-co-
hort models. For the multistate models, the control group
comprised MRSA-uninfected patients in the same hospital
ward during the same time period as the MRSA-infected
patients. For the matched-cohort models, the control group
comprised MRSA-uninfected patients from the hospital’s
administrative database matched for age, sex, and diagnosis.
The authors found that excess LOS with a multistate model
was 11.5 days, and LOS with a matched-cohort model was
15.3 days. However, neither type of model included adjust-
ments for potential confounders such as severity of illness and
empirical antibiotic therapy.
In addition, Lambert et al. [16] used multistate models in a
European multicentre prospective cohort study to assess the
effect of antibiotic resistance on mortality and excess ICU LOS
resulting from healthcare-acquired pneumonia and blood-
stream infections caused by four pathogens. The results
showed that although ICU-acquired pneumonia doubled the
risk of death and bloodstream infections tripled the risk,
antibiotic resistance alone further increased the mortality risk
by only 20%, and resistance did not increase ICU LOS
signiﬁcantly. This study, however, did not adjust for appropri-
ate empirical antibiotic therapy, and the authors did not
consider other confounders, such as age, sex, severity of
illness, or comorbid conditions, while estimating excess LOS.
Similarly, Wolkewitz et al. [17] used a multistate model to
assess the mortality associated with in-hospital bacteraemia
caused by MRSA and methicillin-susceptible S. aureus (MSSA)
up to 90 days after hospital admission. Although a previous
meta-analyses comparing in-hospital mortality associated with
MRSA and MSSA bacteraemia showed that MRSA bacteraemia
signiﬁcantly increased the risk of death compared to MSSA
(OR 1.93, 95% CI 1.54–2.42) [20], in the Wolkewitz et al.
study, the authors found that the odds of mortality for patients
infected with MRSA compared to MSSA were not statistically
signiﬁcant (OR 2.45, 95% CI 0.69–8.70). However, the
authors adjusted only for age, sex, and comorbid conditions
of the patients, discounting other potential confounding
factors, such as severity of illness and empirical antibiotic
therapy.
Limitations and Reasons for Variability in
Studies Estimating the Economic Burden of
Antibiotic Resistance
Economic evaluations of antibiotic resistance have thus far
focused on healthcare settings in high-income countries.
Moreover, they have not attempted to measure the broader
societal value of antibiotics, making the true economic burden
of antibiotic-resistant infections difﬁcult to quantify accurately.
Disregarding the methodological limitations and reasons for
variations in estimates of the disease burden attributable to
antibiotic-resistant infections, several studies [12,21–57] have
reported higher healthcare costs for antibiotic-resistant
infections than for susceptible infections, although these
estimated cost burdens vary widely (Table 3). Most studies
of the economic consequences of antibiotic resistance mea-
sure the excess direct costs incurred by hospitals in managing
resistant infections. These include the costs of increased
hospitalization, diagnostic investigations, treatment, and infec-
tion control. However, as previous reviews have discussed
[7,9], many of these studies do not adjust for inﬂation, and they
do not consider costs from multiple perspectives (patient,
hospital, and society), costs incurred by patients who died, or
marginal costs (Table 4).
In addition to study design limitations, studies reporting cost
estimates vary greatly. Cohen et al. [58] analysed the factors
leading to variation in cost differences in the literature
between patients with antibiotic-resistant infections (cases)
and those with susceptible infections or uninfected people
(controls). The authors found that cost differences were
greater in studies that used uninfected control groups (instead
of those with susceptible infections), studies that compared
total costs instead of post-infection costs only, studies that did
not match cases and controls for LOS prior to infection, and
studies that measured costs as median values rather than as
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means. The authors reported that 84% of the variance in cost
differences between patients with resistant infections and
control patients (either uninfected or those with susceptible
infections) is explained by methodological limitations and
patient-level characteristics.
Limitations in Current Cost Estimates in
Europe and the USA
The overall crude economic burden of antibiotic resistance
was estimated to be at least €1.5 billion in 2007 in Europe and
$55 billion (http://www.tufts.edu/med/apua/consumers/person
al_home_5_1451036133.pdf) in 2000 in the USA, including
patient and hospital costs [59] (Alliance for the Prudent use of
Antibiotics). Indirect patient costswere estimatedon the basis of
forgone earnings resulting from illness or premature death. For
the European estimates, productivity losses accounted for 40%
of the total estimated €1.5 billion, whereas productivity losses
constituted 64% of the total estimated $55 billion for the USA.
Both estimates fail to consider costs for patients or payers
after discharge from the hospital (except for one outpatient
follow-up visit in Europe). Excess healthcare costs for Europe
[59] were estimated based on longer hospital stays for patients
with resistant infections compared to patients with susceptible
infections, and one outpatient follow-up visit with a primary--
care physician after hospitalization. The authors estimated
excess LOS and mortality rates from previous studies
[20,42,48,55,60–63]. These studies, however, did not use
time-dependent exposure models, had small sample sizes, and
some did not adjust for empirical antibiotic therapy.
Similarly, cost estimates for antibiotic-resistant infections in
the USA were estimated based on a single study by Roberts
et al. [64]. This was a single-centre, retrospective, matched
case–control study involving patients infected with antibi-
otic-resistant organisms from both community and healthcare
settings. The overall attributable costs and length of hospital
stay resulting from antibiotic-resistant infections were calcu-
lated by adjusting for healthcare-associated infections, ICU care,
surgery care, and severity of illness, using propensity score and
regression models. Healthcare costs were measured from the
hospital’s perspective and calculated from hospital expenditure
reports and patient resource utilization records. The Roberts
et al. [64] study did not use time-dependent exposure models,
did not adjust for LOS before the onset of hospital-acquired
infection, and used uninfected patients as the control group, as
opposed to patients with susceptible infections.
Factors that Affect Estimates of the
Economic Burden of Antibiotic Resistance
Many factors that could inﬂuence cost estimates associated
with antibiotic resistance are not considered in existing
TABLE 4. Limitations of studies assessing the economic burden of antibiotic-resistant infections
Limitation Description
Failure to use multiple perspectives Studies examining economic burden from only one perspective can underestimate the total effect of resistance. Such perspectives include:
1) Patient and/or payer perspective. Expenses are often incurred after discharge from hospital. Expenses include: rehabilitation
costs; home health services; physician visits; travel costs for healthcare visits
2) Hospital perspective. Hospitals bear costs associated with infection control activities. Costs include: private rooms for isolation;
supplies for isolation measures; delayed discharge to rehabilitation or nursing home because of requirement for private room
3) Societal perspective. Productivity losses, such as lost wages resulting from premature death or absence from work, are
generally estimated in two ways [87]: (i) the human capital approach assumes no unemployment, and captures all lost
productivity attributable to disease mortality by assuming that individuals who died prematurely worked full-time until the end
of their working lives; this could lead to an overestimation of productivity losses; (ii) the friction cost approach captures lost
productivity costs only until a worker would probably be replaced by someone currently unemployed plus transaction costs
associated with identifying a replacement worker
Failure to include costs of patients who died Existing studies typically use excess LOS to calculate costs. However, when a patient dies, costs are often truncated, and lost
wages attributable to premature death are not considered. Costs are then underestimated
Failure to measure long-term marginal costs Marginal costs are incurred by adding units of service. Unlike ﬁxed costs, marginal costs are not easily observable
Failure to adjust for inﬂation Cost estimates from different years should be adjusted for inﬂation by using a standard currency year and a standard currency
unit if currency type varies
LOS, length of stay.
TABLE 3. Excess costs attributable to infections with resistant organisms vs. infections with susceptible organisms
Resistant organism Control Range of excess costa
Methicillin-resistant Staphylococcus aureus Methicillin-susceptible S. aureus $695–$29 030 [21,22,24–36]
Vancomycin-resistant Enterococcus Vancomycin-susceptible Enterococcus $16 711–$60 988 [40–47]
Resistant Pseudomonas aeruginosa Susceptible P. aeruginosa $627–$45 256 [48,49]
Resistant Acinetobacter baumannii Susceptible A. baumannii $5336–$126 856 [23,50–52]
Multiple organisms Susceptible $9372–$18 990 [12,53,54]
ESBL-producing Enterobacteriaceae Non-ESBL-producing Enterobacteriaceae $3658–$4892 [56,57]
ESBL, extended-spectrum b-lactamase.
aIncludes both adjusted and unadjusted estimates; includes only studies reporting cost in US dollars.
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studies, including the rising prevalence of antibiotic resistance,
the consequences of the unavailability of effective antibiotics
where they are most commonly used, and the effect of
antibiotic resistance on broader economic indicators such as
national income, labour supply, and economic growth.
Existing studies estimating the economic burden of antibi-
otic resistance do not consider the changing epidemiology of
resistance and may therefore underestimate the cost. Wide-
spread resistance in either community or healthcare facilities
prompts changes in empirical treatment options, and adverse
health outcomes could lead to extreme ﬁnancial constraints on
the healthcare system and on society. For example, the rise in
the incidence of infections caused by extended-spectrum
b-lactamase (ESBL)-producing Enterobacteriaceae (mainly Esc-
herichia coli) and carbapenem-resistant Enterobacteriaceae
(CRE) is a major concern, as is the emergence of ceftriax-
one-resistant Neisseria gonorrhoea.
E. coli is the most frequent cause of urinary tract and
bloodstream infections people of all ages worldwide [5]. The
Study for Monitoring Antimicrobial Resistance Trends pro-
gramme, which assessed the epidemiology of ESBL producers in
ICU and non-ICU patients with urinary tract infections (UTIs)
between 2010 and 2012 in 55 countries, found that global ESBL
rates for E. coli and Klebsiella pneumoniae exceeded 20% in both
community and hospital patients (3rd Inter science Conference
on Antimicrobial Agents and Chemotherapy, abstract E-1687).
Similarly, the European Antibiotic Resistance Surveillance
System, which includes data from 28 countries for E. coli,
showed that the proportion of third-generation cephalospo-
rin-resistant (surrogate marker for ESBL production) E. coli
bloodstream infections increased from 2.7% in 2003 to 8.3% in
2009 [65]. As the proportion of UTIs caused by ESBL-producing
E. coli increases in the community, UTI-associated bloodstream
infections caused by ESBL-producing E. coli will also rise,
requiring changes in empirical treatment choices for commu-
nity-acquired bloodstream infections to carbapenems (which
are currently considered to be the ‘last resort’ drugs for the
treatment of Gram-negative infections) [66]. This will probably
result in substantial cost increases just for treatment, without
considering the excess costs resulting from associated mor-
bidity and mortality. In addition, the widespread use of
carbapenems for ESBL-producing organisms will augment the
CRE incidence, which could further increase the economic
burden, as treatment options for CRE are limited.
Existing studies also do not take into account the economic
consequences of the unavailability of effective antibiotics
where they are most commonly used. Without effective
antibiotics to treat and prevent infections, diverse ﬁelds of
medicine—including surgery, the care of premature infants,
cancer chemotherapy, and transplantation medicine—will be
severely hampered, and costs will probably rise. Recent studies
have indicated an increasing incidence of infections caused by
antibiotic-resistant bacteria among haematology and cancer
patients [67], solid organ transplant recipients [68–72], and
newborn and paediatric patients [73–78]. With accumulating
evidence of worse clinical outcomes, including increased risk of
death among patients with antibiotic-resistant infections, the
threat of premature death for these groups of immunosup-
pressed patients is increasing. Increased morbidity and
premature death among these patients will impose a signiﬁcant
ﬁnancial burden on the healthcare system and society.
Similarly, antibiotic prophylaxis plays an important role in
preventing surgical site infections. Smith et al. [79] calculated
that if no antibiotics were available to prevent surgical site
infections for patients undergoing total hip replacements, the
postoperative infection rate would be approximately 40–50%,
as compared with the current rate of 0.5–2% with effective
antibiotic prophylaxis. Of the 40–50% of patients who would
have postoperative infections, 30% would die. The number of
patients undergoing replacement surgery would subsequently
drop signiﬁcantly, greatly increasing overall morbidity associ-
ated with hip pain, and leading to potentially large productivity
losses.
Broader Approaches to Estimating the
Economic Burden of Antibiotic Resistance
Most studies considering the costs of antibiotic-resistant
infections take a microeconomic approach that includes health
sector costs. However, Smith et al. [80] argue for a macro-
economic approach that includes larger economic indicators,
such as national income, labour supply, gross domestic product
(GDP), and economic growth.
At least one study has hypothesized that an increase in
resistant infections has the potential to decrease the quality
and quantity of the labour supply, as fewer individuals would
contribute to the labour market, hampering production
activities [81]. According to this argument, as national output
depends on these labour inputs, national output—and subse-
quently national income—would fall. Similarly, decreased
productivity can result in an increase in the cost of produc-
tivity, and, as a result, the prices of goods and services can rise,
which then can decrease total GDP. With a reduction in
demand for goods and services, producers will reduce the use
of labour inputs, causing unemployment and reducing house-
hold income and overall economic growth.
Using a computable general equilibrium (CGE) approach,
Smith et al. [80] demonstrated the macroeconomic conse-
quences of MRSA for the UK. A CGE model is a quantitative
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method for evaluating the effects of economic and policy
‘shocks’ on the economy as a whole. The model uses three
economic agents to describe the economy: consumers,
producers, and the government. Equilibrium represents the
prices at which the level of production and consumption within
each individual sector conﬁrms that the quantity supplied
equals the quantity demanded across all sectors. Antibiotic
resistance is introduced into the model as a shock that alters
labour supply and input productivity. Assuming that 40% of
S. aureus isolates are methicillin-resistant, based on previous
estimates in the UK, a CGE approach shows that this shock
would reduce the labour supply by 0.1% and reduce GDP by
0.4%, equivalent to losses of £3 billion and £11 billion,
respectively.
Conclusion
Estimating the economic burden of antibiotic-resistant bacte-
rial infections remains a challenge. Quantifying the disease
burden attributable to antibiotic resistance is an important
prerequisite. Although resistance has been shown to be
associated with adverse health outcomes, existing studies
quantifying the disease burden have methodological limitations.
Recent studies using multistate models accounting for the
time-varying nature of antibiotic-resistant infections have
reported more conservative estimates of morbidity and
mortality; however, these studies did not address all method-
ological limitations, leaving the true disease burden still largely
unknown. Future studies estimating clinical outcomes of
antibiotic-resistant infections should address the methodolog-
ical limitations by using multistate models with large patient
populations in multicentre settings or by using large adminis-
trative datasets [84].
Similarly, current economic estimates of antibiotic resistance
are limited in scope and do not take into account the wider
societal value of antibiotics, thereby likelymisestimating the true
economic effects of antibiotic resistance. To better quantify the
economic repercussions of antibiotic resistance, future studies
must use macroeconomic approaches that consider the
broader consequences of increasing resistance, including the
loss of antibiotic efﬁcacy in modern medicine. Until we
overcome these challenges, the true disease and economic
burden of antibiotic resistance will remain poorly quantiﬁed.
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